Anticoagulant Therapy for 6 Weeks vs 3 Months and Recurrence and Bleeding in Patients Younger Than 21 Years with Provoked Venous Thromboembolism - Reply

TY - JOUR

T1 - Anticoagulant Therapy for 6 Weeks vs 3 Months and Recurrence and Bleeding in Patients Younger Than 21 Years with Provoked Venous Thromboembolism - Reply

AU - Goldenberg, Neil A.

AU - Brandão, Leonardo R.

AU - Male, Christoph

N1 - Funding Information: Conflict of Interest Disclosures: Dr Smith reported receipt of grants from the National Institute for Health Research (NIHR), UK Research and Innovation, Medical Research Council UK, Zhejiang Province Basic Public Welfare Research Project, Zhejiang Health and Family Planning Commission Programme, Recruitment Program of Global Experts, China, and National Natural Science Foundation of China and receipt of the NIHR Senior Investigator Personal Award. No other disclosures were reported. Funding Information: fees from Anthos Therapeutics, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CPC Clinical Research, Daiichi-Sankyo, Janssen, Novartis, and Pfizer; receiving grants from the National Institutes of Health; and being a member of the Pediatric Antithrombotic Trials Leadership and Steering (Pedi-ATLAS) Group. Dr Brandão reported receiving patient recruitment fees from the National Institutes of Health. Dr Male reported receiving personal fees from Anthos, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, and Pfizer; receiving patient recruitment fees from the National Institutes of Health; being a member of the Pedi-ATLAS Group; being the co-chair of the Antithrombotic Trials Working Group of the International Society for Thrombosis and Hemostasis Pediatric/Neonatal Hemostasis and Thrombosis Subcommittee of the Scientific and Standardization Committee; and being an expert for Connect4Children. Additional Information: A list of the Kids-DOTT Trial Investigators appears in Supplement 4 of the original article. 1. Goldenberg NA, Kittelson JM, Abshire TC, et al; Kids-DOTT Trial Investigators and ATLAS Group. Effect of anticoagulant therapy for 6 weeks vs 3 months on recurrence and bleeding events in patients younger than 21 years of age with provoked venous thromboembolism: the Kids-DOTT randomized clinical trial. JAMA. 2022;327(2):129-137. doi:10.1001/jama.2021.23182 2. Male C, Lensing AWA, Palumbo JS, et al; EINSTEIN-Jr Phase 3 Investigators. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020;7(1):e18-e27. doi:10.1016/S2352-3026(19)30219-4 3. Halton J, Brandão LR, Luciani M, et al; DIVERSITY Trial Investigators. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol. 2021;8(1):e22-e33. doi:10.1016/S2352-3026(20)30368-9 4. Engel ER, Nguyen ATH, Amankwah EK, et al. Predictors of postthrombotic syndrome in pediatric thrombosis: a systematic review and meta-analysis of the literature. J Thromb Haemost. 2020;18(10):2601-2612. doi:10.1111/jth.14984 5. Avila L, Amiri N, De R, et al. Characteristics of upper-and lower-extremity deep vein thrombosis and predictors of postthrombotic syndrome in children. Blood Adv. 2021;5(19):3737-3747. 6. Betensky M, Amankwah EK, Brandal S, Everett AD, Goldenberg NA. Plasma fibrinolysis, inflammatory markers, and postthrombotic syndrome: preliminary findings from the Kids-DOTT Biobank. Blood Adv. 2021;5(1):233-239. doi:10. 1182/bloodadvances.2020002974

PY - 2022/5/3

Y1 - 2022/5/3

UR - https://www.scopus.com/pages/publications/85129380715

UR - https://www.scopus.com/pages/publications/85129380715#tab=citedBy

U2 - 10.1001/jama.2022.3729

DO - 10.1001/jama.2022.3729

M3 - Letter

C2 - 35503347

AN - SCOPUS:85129380715

SN - 0098-7484

VL - 327

SP - 1709

EP - 1710

JO - JAMA

JF - JAMA

IS - 17

ER -